Download het volledig rapport (302 p.) - KCE

KCE reports vol. 6A Prenatale zorg 134
Study Ref Population Intervention Outcomes
mother-to-child
Results Comments Study
type
transmission with no Reduction of risk of
antiretroviral mother-to-child
treatment and vaginal transmission with no
or emergency antiretroviral treatment
caesarean section vs. and vaginal or emergency
elective caesarean caesarean section vs.
section and
elective caesarean section
antiretroviral therapy and antiretroviral therapy:
31.6% (13.6% to 52.2%) to
4.2% (0.8% to 8.5%)
Short short (treatment with zidovudine) = 35 weeks in pregnancy for mother and until 3 days old for baby
Long long (treatment with zidovudine) = from 28 weeks in pregnancy for mother and for the baby until 6 weeks old
Long short (treatment with zidovudine) = from 28 weeks pregnancy for the mother and for the baby until it is 3 days old
Short long (treatment with zidovudine) = from 35 weeks in pregnancy for the mother and for the baby until 6 weeks old
Does screening for HIV in pregnancy and instituting appropriate interventions lead to improved maternal and perinatal outcomes?
Study Ref Population Intervention Outcomes Results Comments Study
Brocklehurst
and Volmink,
2002
4
[416]
8 RCTs total, various
countries, HIV infected,
pregnant women
Cochrane review
Most recent update 2002
Zidovudine vs. placebo
Zidovudine
vs.zidovudine
Short short vs. longlong
Long short vs. long
long
Short long vs. long
long
Infant death within 1
year of birth (n=1487,
4RCT´s)
Infant death within 28
days of birth (n = 1210,
3 RCTs)
Infant death after 1 year
of birth (n = 395, 1
RCT)
Incidence of stillbirth (n
= 1504, 4 RCTs)
OR 0.57 (95% CI 0.38 to
0.85)
OR 1.87 (95% CI 0.68 to
5.10)
OR 1.02 (95% CI 0.14 to
7.28)
OR 0.83 (95% CI 0.36 to
1.92)
* Significant
heterogenity between
RCTs
** Number of maternal
deaths small and wide
CIs
*** This study was
double-blind with
central randomisation
EL
EL
type
SR 1a